Source: RegeneRx Biopharmaceuticals, Inc. and reported by http://www.prnewswire.com/
ROCKVILLE, Md., Dec. 4, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Chinese State Intellectual Property Office (SIPO) has issued a patent for a key peptide fragment of Thymosin beta 4 (TB4) to RegeneRx. The patent claims are directed to both composition of matter and methods of use, including suppressing inflammation, stimulating cell migration, protecting tissue from cytotoxicity, inhibiting apoptosis, inhibiting tissue damage caused by UV radiation, and stimulating elastin, among others. The patent expiry is expected to be in 2029.
"This is one of two biologically active peptide fragments of TB4 that we are interested in because, as demonstrated in a number of animal models, we believe they have properties potentially useful in medical and cosmeceutical product candidates. We are pleased that we received this patent in China, which has significant market potential for such products," stated Dr. Allan L. Goldstein, Emeritus Professor and Chairman of the Department of Biochemistry and Molecular Medicine at The George Washington University School of Medicine and RegeneRx's chief scientific advisor.
Read more: http://www.prnewswire.com/news-releases/regenerx-receives-chinese-patent-for-key-tb4-peptide-fragment-300188201.html